Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 337-348

  Yin, Jie ^a   Yan, Xuedong ^a,d   Yao, Xin ^a   Zhang, Yongli ^a   Shan, Ying ^a   Mao, Ning ^b   Yang, Yili ^c   Pan, Lingya ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Annexin A3; Biomarker; Drug resistance; Ovarian cancer; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; PLATINUM; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CULTURE MEDIUM; DRUG RESISTANCE; EXOCYTOSIS; EXOSOME; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

AGED; ANNEXIN A3; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DRUG RESISTANCE, NEOPLASM; EXOCYTOSIS; EXOSOMES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84863010943     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01316.x     Document Type: Article

References (37)

1. Berek JS. Practical gynecologic oncology. Philadelphia Lippincott Williams & Wilkins; 2000.
2. Hamada S, Kamada M, Furumoto H, et al. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol. 1994; 52: 313-9.
3. Veneroni S, Zaffaroni N, Daidone MG, et al. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer. 1994; 30: 1002-7.
4. Sasaki H, Sheng Y, Kotsuji F, et al. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000; 60: 5659-66.
5. Marth C, Widschwendter M, Kaern J, et al. Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br J Cancer. 1997; 76: 1328-32.
6. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996; 56: 3087-90.
7. Yan XD, Pan LY, Yuan Y, et al. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res. 2007; 6: 772-80.
8. Yan XD, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010; 70: 1616-24.
9. Morgan RO, Fernandez MP. Annexin gene structures and molecular evolutionary genetics. Cell Mol Life Sci. 1997; 53: 508-15.
10. 2+ signaling to membrane dynamics. Nat Rev Mol Cell Biol. 2005; 6: 449-61.
11. Gerke V, Creutz CE, Moss SE. Annexins: from structure to function. Physiol Rev. 2002; 82: 331-71.
12. Pellicciari C, Bottone MG, Biggiogera M. Detection of apoptotic cells by annexin V labeling at electron microscopy. Eur J Histochem. 1997; 41: 211-6.
13. Seaton BA, Dedman JR. Annexins. Biometals. 1998; 11: 339-404.
14. 2+-dependent aggregation of isolated specific granules. J Clin Invest. 1990; 85: 1065-71.
15. Chu CS, Thigpen JT. The role of chemotherapy in gynecologic cancer. In: Rubin SC, editor. Chemotherapy of gynecologic cancer. 2nd ed. Philadephia Lippincott Williams & Wilkins; 2004. pp. 101-25.
16. Toda T, Takeya K, Koike M, et al. Electron microscopy of ultrathin sections of Mycobacterium. I. Fine structures of the cells grown in-vitro and in-vivo. Proc Jpn Acad. 1960; 36: 372-5.
17. Bello V, Mattei G, Mazzoldi P, et al. Transmission electron microscopy of lipid vesicles for drug delivery: comparison between positive and negative staining. Microsc Microanal. 2010; 16: 456-61.
18. Milne RG. Solid phase immune electron microscopy of virus preparations. In: Hyatt AD, Eaton BT, editors. Immuno-gold electron microscopy in virus diagnosis and research. Boca Raton CRC Press; 1993. pp. 25-70.
19. Lamparski HG, Metha-Damani A, Yao JY, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002; 270: 211-26.
20. Ma AS, Bell DJ, Mittal AA, et al. Immunocytochemical detection of extracellular annexin II in cultured human skin keratinocytes and isolation of annexin II isoforms enriched in the extracellular pool. J Cell Sci. 1994; 107: 1973-84.
21. Faure AV, Migne C, Devilliers G, et al. Annexin 2 "secretion" accompanying exocytosis of chromaffin cells: possible mechanisms of annexin release. Exp Cell Res. 2002; 276: 79-89.
22. Schostak M, Schwall GP, Poznanovic S, et al. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol. 2009; 181: 343-53.
23. Futter CE, White IJ. Annexins and endocytosis. Traffic. 2007; 8: 951-8.
24. Donnelly SR, Moss SE. Annexins in the secretory pathway. Cell Mol Life Sci. 1997; 53: 533-8.
25. Sotelo JR, Porter KR. An electron microscope study of the rat ovum. J Biophys Biochem Cytol. 1959; 5: 327-42.
26. Danielsen EM, van Deurs B, Hansen GH. "Nonclassical" secretion of annexin A2 to the lumenal side of the enterocyte brush border membrane. Biochemistry. 2003; 42: 14670-6.
27. Hansen GH, Immerdal L, Thorsen E, et al. Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytes. J Biol Chem. 2001; 276: 32338-44.
28. Simpson RJ, Lim JW, Moritz RL, et al. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009; 6: 267-83.
29. Madoz-Gurpide J, Lopez-Serra P, Martinez-Torrecuadrada JL, et al. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics. 2006; 5: 1471-83.
30. Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009; 217: 54-64.
31. Wozny W, Schroer K, Schwall GP, et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics. 2007; 7: 313-22.
32. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol. 2009; 112: 275-81.
33. Wang Y, Serfass L, Roy MO, et al. Annexin-I expression modulates drug resistance in tumour cells. Biochem Biophys Res Commun. 2004; 314: 565-70.
34. Han EK, Tahir SK, Cherian SP, et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer. 2000; 83: 83-8.
35. Miao Y, Cai B, Liu L, et al. Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2009; 19: 1545-9.
36. Kim A, Enmoto T, Serada S, et al. Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009; 125: 2316-22.
37. Bianchi C, Bombelli S, Raimondo F, et al. Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isofroms of annexin A3. Am J Pathol. 2010; 176: 1660-70.